Indoco Remedies profit and loss

Latest FY26

Revenue: ₹1,845cr+10.8% on FY25
EBITDA: ₹142cr+42.9% on FY25
Net profit: −₹98.7cr−₹78.0 cr in FY25
EPS: −₹10.70₹8.46 in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	1,909	1,845	1,665	1,817	1,669	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	5.1	3.3	5.5	9.9	2.3
	1,914	1,849	1,670	1,827	1,671
	439	426	396	485	412
	161	144	141	116	103
	−1.2	−27.4	−39.0	−41.5	6.6
	422	426	394	362	323
	127	122	66.2	38.0	25.0
	133	126	114	91.9	70.6
	719	736	673	652	539
	2,000	1,952	1,746	1,703	1,478
	169	142	99.3	244	286
	35.2	15.4	−14.6	152	215
Profit
	−86.5	−104	−75.4	124	193
	132	−2.9	1.0	11.5	0.0
	45.6	−107	−74.4	136	193
	22.2	3.0	0.5	33.2	55.5
	−8.4	−10.8	3.1	5.6	−5.0
	13.8	−7.8	3.6	38.8	50.6
	31.8	−98.7	−78.0	97.0	142
	31.8	−98.7	−78.0	97.0	142
	10.5	12.6	−4.1	0.3	1.4
	42.3	−86.1	−82.1	97.3	144
	31.9	−95.2	−73.7	98.5	142
	−0.2	−3.6	−4.2	−1.5	—
Per share
	₹3.43	−₹10.70	₹8.46	₹10.53	₹15.44
	₹3.45	−₹10.69	₹8.45	₹10.51	₹15.42
Other comprehensive income — detail
	10.5	12.6	−4.1	—	—
	2.1	1.8	−6.0	0.1	1.9
	0.5	0.5	−1.5	—	—
	—	—	—	0.0	0.5
	9.4	12.6	0.3	0.2	—
	0.5	1.4	−0.1	—	—
	42.5	−82.5	−77.9	98.7	144
	−0.2	−3.6	−4.2	−1.5	0.0
Per share — as-filed variants
	₹3.43	−₹10.70	₹8.46	₹10.53	₹15.44
	₹3.45	−₹10.69	₹8.45	₹10.51	₹15.42
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,309	1,304	1,167	1,258	1,147
	68.6%	70.6%	70.1%	69.2%	68.8%
Adjusted (ex-exceptional items) — derived
	−86.5	−104	−75.4	124	193
	132	−2.9	1.0	11.5	0.0
	−60.3	−96.0	−78.9	88.8	142
	−₹6.50	−₹10.40	₹8.57	₹9.64	₹15.44

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

INDOCO₹213.75

Indoco Remedies Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSAIPARENT PANACEABIO HIKAL WINDLAS HESTERBIO DCAL SYNCOMF SOLARAMcap ₹1,973 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	1,668.6	1,817.3	1,664.9	1,845.3	1,908.6
Other Income	2.3	9.9	5.5	3.3	5.1
Total Income	1,671.0	1,827.1	1,670.4	1,848.7	1,913.7
Expenses
+ Cost of Materials Consumed	412.0	485.0	396.3	425.6	439.3
+ Purchases of Stock-in-Trade	102.7	115.7	140.9	143.6	161.2
+ Changes in Inventories	6.6	-41.5	-39.0	-27.4	-1.2
+ Employee Benefit Expense	322.6	361.9	394.1	425.7	422.0
+ Finance Costs	25.0	38.0	66.2	122.3	126.8
+ Depreciation & Amortisation	70.6	91.9	113.8	126.5	133.5
+ Other Expenses	538.6	651.9	673.4	736.1	718.7
Total Expenses	1,478.2	1,702.9	1,745.7	1,952.2	2,000.2
EBITDA	286.1	244.3	99.3	141.8	168.7
EBIT	215.5	152.4	-14.6	15.4	35.2
Profit
PBT before Exceptional Items	192.8	124.3	-75.4	-103.6	-86.5
+ Exceptional Items	0.0	11.5	1.0	-2.9	132.1
Pretax Income	192.8	135.8	-74.4	-106.5	45.6
+ Current Tax	55.5	33.2	0.5	3.0	22.2
+ Deferred Tax	-5.0	5.6	3.1	-10.8	-8.4
Tax Expense	50.6	38.8	3.6	-7.8	13.8
Net Income	142.3	97.0	-78.0	-98.7	31.8
+ Net Income — Continuing Ops	142.3	97.0	-78.0	-98.7	31.8
+ Other Comprehensive Income	1.4	0.3	-4.1	12.6	10.5
Total Comprehensive Income	143.7	97.3	-82.1	-86.1	42.3
Net Income to Common	142.3	98.5	-73.7	-95.2	31.9
Minority Interest	—	-1.5	-4.2	-3.6	-0.2
Per Share
Basic EPS	15.44	10.53	8.46	-10.70	3.43
Diluted EPS	15.42	10.51	8.45	-10.69	3.45
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-4.1	12.6	10.5
+ Items NOT to be Reclassified to P&L	1.9	0.1	-6.0	1.8	2.1
+ Tax on Items NOT to be Reclassified	—	—	-1.5	0.5	0.5
+ Tax on Items NOT to be Reclassified — alt tag	0.5	0.0	—	—	—
+ Items to be Reclassified to P&L	—	0.2	0.3	12.6	9.4
+ Tax on Items to be Reclassified	—	—	-0.1	1.4	0.5
Comprehensive Income — Owners of Parent	143.7	98.7	-77.9	-82.5	42.5
Comprehensive Income — Non-controlling Interests	0.0	-1.5	-4.2	-3.6	-0.2
Per Share — as-filed variants
Basic EPS — Continuing Operations	15.44	10.53	8.46	-10.70	3.43
Diluted EPS — Continuing Operations	15.42	10.51	8.45	-10.69	3.45
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,147.3	1,258.1	1,166.7	1,303.6	1,309.3
Gross Margin %	68.76	69.23	70.08	70.64	68.60
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	192.8	124.3	-75.4	-103.6	-86.5
− Exceptional Items (reconciliation)	0.0	11.5	1.0	-2.9	132.1
Net Income Adj (tax-effected)	142.3	88.8	-78.9	-96.0	-60.3
EPS Adj	15.44	9.64	8.57	-10.40	-6.50
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	18.4	18.4	18.5	18.5	18.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.